Abstract
Salivary duct carcinoma (SDC) is a rare subtype of salivary gland carcinoma and is considered to be a high-grade aggressive tumor with morphological resemblance to ductal carcinoma of the breast. We present a case of a patient who suffered from metastatic SDC that was positive for human epidermal growth factor receptor-2 (HER-2) and attained complete objective response, as seen on PET-CT after combined treatment with paclitaxel, carboplatin, and trastuzumab.
This is a preview of subscription content, log in via an institution to check access.
References
Slamon DJ, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.
Press MF, et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res. 1994;54:5675–82.
Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol. 2006;24:2673–8.
Glisson B, et al. HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res. 2004;10:944–6.
Nabili V, Tan JW, Bhuta S, Sercarz JA, Head CS. Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy. Head Neck. 2007;29:907–11.
Haddad R, Posner MR. Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine. Clin Adv Hematol Oncol. 2003;1:226–8.
Haddad R, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003;39:724–7.
Cornolti G, et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch Otolaryngol Head Neck Surg. 2007;133:1031–6.
Robert N, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–92.
Seifert G, Brocheriou C, Cardesa A, Eveson JW. WHO international histological classification of tumours. Tentative histological classification of salivary gland tumours. Pathol Res Pract. 1990;186:555–81.
Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol. 2001;12(Suppl 1):S81–7.
Skálová A, et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology. 2003;42:348–56.
Skálová A, Stárek I, Kucerová V, Szépe P, Plank L. Salivary duct carcinoma–a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract. 2001;197:621–6.
Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl Immunohistochem Mol Morphol. 2008;16:54–8.
Prat A, et al. Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2008;30:680–3.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaidar-Person, O., Billan, S. & Kuten, A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 29, 704–706 (2012). https://doi.org/10.1007/s12032-011-9884-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12032-011-9884-1